Platelet aggregation inhibitors in neurology.

Author: KeyserA

Paper Details 
Original Abstract of the Article :
This literature review reports on secondary prevention of ischaemic stroke. The aim of secondary prevention is to protect patients who belong to a risk group from the occurrence of brain infarction. Symptomatic patients with a demonstrated carotid artery stenosis of 70% and more will most probably b...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1007/BF01871125

データ提供:米国国立医学図書館(NLM)

Platelet Aggregation Inhibitors: A Lifeline in the Desert of Ischaemic Stroke

Ischaemic stroke, a devastating event that can lead to permanent brain damage, is like a sudden sandstorm in the desert of health. This review, akin to a comprehensive guide for navigating this treacherous terrain, explores the role of platelet aggregation inhibitors in the secondary prevention of ischaemic stroke.

Platelet Aggregation Inhibitors: A Valuable Tool for Stroke Prevention

The review highlights the effectiveness of acetylsalicylic acid (aspirin) in reducing the risk of ischaemic stroke, particularly in patients with carotid artery stenosis. The researchers also emphasize the potential benefits of combining aspirin with dipyridamole, suggesting a synergistic effect in reducing stroke risk.

Navigating the Desert of Stroke Prevention

This review underscores the importance of platelet aggregation inhibitors in the secondary prevention of ischaemic stroke. It emphasizes the need for individualized treatment approaches, considering the specific risk factors and potential benefits of various medications.

Dr.Camel's Conclusion

This review provides a valuable guide for navigating the desert of ischaemic stroke prevention. It highlights the crucial role of platelet aggregation inhibitors, such as aspirin and dipyridamole, in reducing stroke risk. The researchers emphasize the need for personalized treatment plans, carefully considering individual risk factors to ensure optimal stroke prevention.

Date :
  1. Date Completed 1994-03-04
  2. Date Revised 2019-11-01
Further Info :

Pubmed ID

8298583

DOI: Digital Object Identifier

10.1007/BF01871125

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.